The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure
- PMID: 884803
- DOI: 10.1161/01.cir.56.3.468
The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure
Abstract
Twenty-five patients with left ventricular failure and low cardiac output received a 72 hour infusion of dobutamine (10-15 microgram/kg/min) in order to determine the cardiovascular properties of this new inotropic agent. Left ventricular contractile performance improved significantly during the infusion as measured by systolic time intervals and echocardiographic parameters. Mean PEP/LVET decreased from 0.76 +/- 0.03 to 0.58 +/- 0.03 (P less than 0.05). The percent change in internal dimension of the left ventricle from diastole to systole increased from 9.5 +/- 1 to 16.8 +/- 1 (P less than 0.05) and Vcf increased from 0.47 +/- 0.05 to 0.80 +/- 0.06 circ/sec (P less than 0.05). Mean cardiac output (nine patients) rose from 1.97 +/- 0.15 to 3.33 +/- 0.50 L/min/m2 while mean pulmonary capillary wedge pressure fell from 28 +/- 3 to 18 +/- 2 mm Hg during the infusion period (both P less than 0.05). These changes in cardiac function occurred without significant changes in heart rate, ventricular irritability, or blood pressure. Urine flow and urine sodium concentration increased during the infusion period. The improvement of cardiac function without the simultaneous development or exacerbation of undesirable effects (tachycardia, premature ventricular contractions, increased pulmonary or systemic resistance, tachyphylaxis, etc.) makes dobutamine a highly desirable inotropic agent.
Similar articles
-
Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure.Circulation. 1977 Feb;55(2):375-8. doi: 10.1161/01.cir.55.2.375. Circulation. 1977. PMID: 318933 Clinical Trial.
-
Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure.Circulation. 1977 Oct;56(4 Pt 1):528-33. doi: 10.1161/01.cir.56.4.528. Circulation. 1977. PMID: 902377
-
Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure.Circulation. 1978 Sep;58(3 Pt 1):466-75. doi: 10.1161/01.cir.58.3.466. Circulation. 1978. PMID: 679437
-
Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine.Prog Cardiovasc Dis. 1977 Jan-Feb;19(4):327-40. doi: 10.1016/0033-0620(77)90007-x. Prog Cardiovasc Dis. 1977. PMID: 12536 Review. No abstract available.
-
Review of intermittent dobutamine infusions for congestive cardiomyopathy.Pharmacotherapy. 1987;7(2):47-53. doi: 10.1002/j.1875-9114.1987.tb03514.x. Pharmacotherapy. 1987. PMID: 3299303 Review.
Cited by
-
Bretylium and dobutamine in the treatment of coronary artery disease.Bull N Y Acad Med. 1979 Sep;55(8):798-809. Bull N Y Acad Med. 1979. PMID: 290401 Free PMC article. No abstract available.
-
Effects of short-term administration of dobutamine on left ventricular performance, exercise capacity, norepinephrine levels, and lymphocyte adrenergic receptor density in congestive heart failure.Cardiovasc Drugs Ther. 1990 Aug;4(4):1105-11. doi: 10.1007/BF01856506. Cardiovasc Drugs Ther. 1990. PMID: 1964577
-
Haemodynamic effects of dobutamine in patients with congestive heart failure receiving captopril.Br Heart J. 1981 Nov;46(5):528-30. doi: 10.1136/hrt.46.5.528. Br Heart J. 1981. PMID: 7032556 Free PMC article.
-
Haemodynamic effects of oral salbutamol alone and in combination with sublingual isosorbide dinitrate in patients with severe congestive cardiac failure.Br Heart J. 1980 Feb;43(2):220-5. doi: 10.1136/hrt.43.2.220. Br Heart J. 1980. PMID: 7362716 Free PMC article.
-
Intravenous vasodilator therapy in congestive heart failure.Drugs Aging. 2003;20(7):485-508. doi: 10.2165/00002512-200320070-00002. Drugs Aging. 2003. PMID: 12749747 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
